Evidence map›Paper›PMID 39052715›Full record

Trial reportThe Journal of infectious diseases2024

Minimal Impact on the Resistome of Children in Botswana After Azithromycin Treatment for Acute Severe Diarrheal Disease.

Allison K Guitor, Anna Katyukhina, Margaret Mokomane, Kwana Lechiile, David M Goldfarb, Gerard D Wright, Andrew G McArthur, Jeffrey M Pernica

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02803827 (Optimizing the Management of Pediatric Acute Diarrhoeal Disease in Botswana), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02803827 phase3completednot on this map

Optimizing the Management of Pediatric Acute Diarrhoeal Disease in Botswana

TypeinterventionalSponsorHamilton Health Sciences CorporationRan2016 to 2019Enrolled276ConditionsAcute GastroenteritisArmsRapid diagnostics, Probiotic, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Allison K GuitorDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-6290-6233
Anna KatyukhinaDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
Margaret MokomaneSchool of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.
Kwana LechiileBotswana-University of Pennsylvania Partnership, Gaborone, Botswana.
David M GoldfarbBotswana-University of Pennsylvania Partnership, Gaborone, Botswana.
Gerard D WrightDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-9129-7131
Andrew G McArthurDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
Jeffrey M PernicaMichael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada.

Funding

bioMérieuxCIHR GSD-164145Cisco Systems CanadaGrand Challenges CanadaHewlett Packard EnterpriseMcMaster UniversityPure Storage
6 · The paper itself

Abstract

backgroundMacrolide antibiotics, including azithromycin, can reduce under 5 years of age mortality rates and treat various infections in children in sub-Saharan Africa. These exposures, however, can select for antibiotic-resistant bacteria in the gut microbiota.

methodsOur previous randomized controlled trial (RCT) of a rapid-test-and-treat strategy for severe acute diarrheal disease in children in Botswana included an intervention (3-day azithromycin dose) group and a control group that received supportive treatment. In this prospective matched cohort study using stools collected at baseline and 60 days after treatment from RCT participants, the collection of antibiotic resistance genes or resistome was compared between groups.

resultsCertain macrolide resistance genes increased in prevalence by 13%-55% at 60 days, without differences in gene presence between the intervention and control groups. These genes were linked to tetracycline resistance genes and mobile genetic elements.

conclusionsAzithromycin treatment for bacterial diarrhea for young children in Botswana resulted in similar effects on the gut resistome as the supportive treatment and did not provide additional selective pressure for macrolide resistance gene maintenance. The gut microbiota of these children contains diverse macrolide resistance genes that may be transferred within the gut upon repeated exposures to azithromycin or coselected by other antibiotics. CLINICAL TRIALS REGISTRATION: NCT02803827.

Indexed as

Anti-Bacterial AgentsAzithromycinDiarrheaGastrointestinal MicrobiomeBacteriaBotswanaChild, PreschoolDrug Resistance, BacterialFecesFemaleHumansInfantMaleProspective StudiesAnti-Bacterial AgentsAzithromycinantibiotic resistanceazithromycinbacterial diarrhea

Identifiers

PMID39052715
PMCPMC11272098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.